

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Sinopharm Tech Holdings Limited**

**國藥科技股份有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8156)**

### **INSIDE INFORMATION**

#### **FURTHER ADJOURNMENT OF WINDING-UP PETITION HEARING**

This announcement is made by Sinopharm Tech Holdings Limited (the “**Company**”) pursuant to Rule 17.10(2) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

References are made to the announcements of the Company dated 19 September 2023, 15 November 2023 and 7 February 2024 (the “**Announcements**”) in relation to the Petition filed by the Petitioner against the Company. Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Announcements.

The Company would like to update the shareholders of the Company that, at the hearing on 3 April 2024, the High Court ordered that the hearing of the Petition be further adjourned to 8 May 2024.

Further announcement(s) will be made by the Company to inform the public on any material development of the Petition as and when appropriate.

**Shareholders of the Company and other investors are reminded to consider the related risks and exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Sinopharm Tech Holdings Limited**  
國藥科技股份有限公司  
**HO Kam Kin**  
*Executive Director*

Hong Kong, 3 April 2024

*As at the date of this announcement, the Board comprises Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Mr. HSU Dong An and Mr. HEUNG Pik Lun as independent non-executive Directors.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at [www.hkexnews.hk](http://www.hkexnews.hk) for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.*